Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28071819 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL399572 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL7088576 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL12952342 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL17320247 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL4938419 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL6981275 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL4938867 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL13282093 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| Hydrochloric Acid SCHEMBL31029934 | 0.98 | ALDH1A1 (0.50) | ALDH1A1CYP2C19RAB9APOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475263-B1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11524955-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20200299276-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10710983-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-2953457-B1 | ERK INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2020-04-08 | — | — | EP | disclosed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-20170369476-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-9796708-B2 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | CEPHALON, INC. | 2014-11-27 | — | — | US | disclosed |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | CEPHALON, INC. | 2014-11-27 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8030483-B2 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
| US-20090176981-A1 | Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1812581-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE N-CARBAMATE PROTECTED BETA-LACTAMS BY OPTICAL RESOLUTION EMPLOYING A CANDIDA ANTARCTICA LIPASE | RIGEL PHARMACEUTICALS INC (US) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | ALDH1A1 899/4885CYP2C19 1329/4885RAB9A 3560/4885 |
| US-11524955-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | IRAK4, IRAK1, IRAK3 | ALDH1A1 3336/4885CYP2C19 3869/4885RAB9A 3906/4885 |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | JAK1, ALK, JAK2 | ALDH1A1 653/4885CYP2C19 1852/4885RAB9A 2162/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | ALDH1A1 2289/4885CYP2C19 4330/4885RAB9A 1454/4885 |
| US-20170369476-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK4, IRAK1, IRAK2 | ALDH1A1 2531/4885CYP2C19 2799/4885RAB9A 3941/4885 |
| US-20090176981-A1 | Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, CCNI | ALDH1A1 659/4885CYP2C19 2391/4885RAB9A 3384/4885 |
| US-10710983-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | IRAK4, IRAK1, IRAK2 | ALDH1A1 2531/4885CYP2C19 2799/4885RAB9A 3941/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | ALDH1A1 2838/4885CYP2C19 3997/4885RAB9A 1517/4885 |
| US-20200299276-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK4, IRAK1, IRAK3 | ALDH1A1 3318/4885CYP2C19 3975/4885RAB9A 3878/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | ALDH1A1 2838/4885CYP2C19 3997/4885RAB9A 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.